Fig. 5 | Nature Communications

Fig. 5

From: Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC

Fig. 5The alternative text for this image may have been generated using AI.

PHGDH inhibitor sensitized HCC cells to Sorafenib treatment. a NCT-503 inhibited HCC cell proliferation in a dose-dependent manner with 50% growth inhibiting (GI50) at 50 µM. b Treatment of NCT-503 at 40 μM for 48 h significantly reduced the relative ratio of NAPDH/NAD+in HCC cells. c Annexin V-PI staining showed that NCT-503 worked synergistically with Sorafenib to induce HCC cell apoptosis. d Both NCT-503 and Sorafenib inhibited HCC tumorigenicity. NCT-503 and Sorafenib combination therapy effectively abolished HCC growth in the nude mice model (blue connected dots: vehicle-treated group; red connected dots: Sorafenib-treated group; green connected dots: NCT-503-treated group; purple connected dots: Sorafenib and NCT-503-treated group). The error bar in panels b and c represents the SEM, n = 3 biological independent samples. The error bar in panel d represents the SD, n = 6 mice. Source data are provided as a Source Data file (Student's t-test *P < 0.05, **P < 0.01, ***P < 0.001)

Back to article page